Market Overview

The global hereditary angioedema market is expected to grow at a CAGR of 8.8%

Share:

The global hereditary angioedema market is expected to grow at a CAGR of 8.8%

PR Newswire

NEW YORK, August 8, 2018 /PRNewswire/ -- C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze, Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies

Read the full report: https://www.reportlinker.com/p05471642

Report Details
The global hereditary angioedema market is expected to grow at a CAGR of 8.8% in the first half of the forecast period. In 2017, the C1 Esterase Inhibitor segment held 42% of this market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 232-page report you will receive 82 tables and 130 figures– all unavailable elsewhere.
The 232-page report provides clear detailed insight into the global hereditary angioedema market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
• Global Hereditary Angioedema Market Forecast from 2018-2028

This report also breaks down the revenue forecast for the global hereditary angioedema market by drug class:
• C1 Esterase Inhibitor: Cinryze, Berinert, Ruconest
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor (Kalbitor)

This report also provides a market attractiveness index by drug class.

This report also breaks down the revenue forecast for the global hereditary angioedema market by route of administration:
• Intravenous
• Subcutaneous Injection
• Oral

This report also provides a market attractiveness index by route of administration.

This report also breaks down the revenue forecast for the global hereditary angioedema market by distribution channel:
• Hospital Pharmacies
• Retail Pharmacies

This report also provides a market attractiveness index by distribution channel

This report provides individual revenue forecasts to 2028 for these regional and national markets:
North America: The U.S., Canada
Latin America: Brazil, Mexico, Rest of Latin America
Europe: U.K., Germany, Spain, France, Italy, Russia, Rest of Europe
Asia-Pacific: China, India, Japan, Australia and New Zealand, South Korea, ASEAN, Rest of Asia-Pacific
Middle East: GCC Countries, Israel, Rest of Middle East
Africa: South Africa, Central Africa, North Africa

This report also provides a market attractiveness index by region
The forecast for each regional market is further broken down by drug class, product, route of administration and distribution channel
This report provides a market attractiveness index by drug class, product, route of administration and distribution channel for each regional market

Our study discusses the selected leading companies that are the major players in the global hereditary angioedema industry: 
• BioCryst Pharmaceuticals, Inc. 
• CSL Limited 
• iBio, Inc. 
• Ionis Pharmaceuticals, Inc. 
• Pharming Group NV 
• Santarus, Inc. 
• Shire PLC 
• This report discusses factors that drive and restrain the market, as well as trends and opportunities. 
 

Read the full report: https://www.reportlinker.com/p05471642

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-hereditary-angioedema-market-is-expected-to-grow-at-a-cagr-of-8-8-300694175.html

SOURCE Reportlinker

View Comments and Join the Discussion!